Compare Boston Scientific Corporation (BSX) vs Global X Uranium ETF (URA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Global X Uranium ETF — how do they compare? Boston Scientific Corporation trades at $42.67 (market cap $66.37B), while Global X Uranium ETF trades at $41.48. The key difference: Global X Uranium ETF is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| BSX | URA | |
|---|---|---|
Market Cap | $66.37B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $108.14 | $61.81 |
52-Week Low | $42.63 | $36.45 |
Enterprise Value | $75.94B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
URA (Global X Uranium ETF) trades at $40.72, down 5.24% over 24 hours amid bearish technical signals. The ETF faces selling pressure with all 13 moving averages signaling bearish momentum, though RSI indicators suggest potential oversold conditions. Recent news highlights uranium's strategic positioning at the intersection of AI power demand and nuclear energy revival, with the fund holding $6.29 billion in assets across 56 uranium-related companies.
The ETF's outlook balances near-term technical weakness against strong secular tailwinds from AI-driven electricity demand and nuclear policy support. Key risks include uranium price volatility and competition from pure-miner alternatives, while the current oversold technical condition may present entry opportunities for long-term investors betting on nuclear energy adoption.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Global X Uranium ETF
URA provides broad exposure to the global uranium industry and nuclear energy sector. Unlike pure-play mining funds, it includes companies involved in nuclear component production and infrastructure, with top 2026 holdings such as Cameco, Oklo, and Uranium Energy Corp.
Read more on URA →
